Vaia Lida Chatzi, MD, PhD

Professor of Population and Public Health Sciences and Pediatrics

Center Director for Center for Translational Exposomics Research (CTER)

EMERGE Pre-Institute Director

Image of Vaia Lida Chatzi, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Lida Chatzi is a physician, environmental epidemiologist, and Professor of Population and Public Health Sciences in the Division of Environmental Health at the University of Southern California (USC). She has over 20 years of experience in environmental health research with a strong track record of productivity in multidisciplinary, translational science. Her work focuses on the effects of environmental chemical exposures on human health by integrating data from epidemiologic cohorts and experimental models.
Dr. Chatzi serves as Director of the USC Center for Translational Research on Environmental Health (USC-R-TEN), Director of the NIEHS-funded Southern California Superfund Research Program for PFAS Assessment, Remediation, and Prevention (ShARP), and Deputy Director of the NIEHS-funded P30 Southern California Environmental Health Sciences Center (SCEHSC). Through these leadership roles, she directs teams focused on bench-to-population science, community-engaged, solution-oriented research, and transdisciplinary career development.
Her research program is dedicated to understanding how environmental pollutants—particularly endocrine-disrupting chemicals such as PFAS—influence metabolic health outcomes across the life course. Her studies examine links between chemical exposures and obesity, type 2 diabetes, insulin resistance, liver disease, and cancer.
Dr. Chatzi leads several large, multi-center studies in Southern California and has established transatlantic collaborations to leverage intellectual resources and population cohorts in both the U.S. and Europe. She is principal investigator on multiple NIH/NIEHS and EU-funded research initiatives aimed at advancing precision environmental health through integrative exposomics and multi-omics approaches.

Awards

  • Department of Public Health, University of Sheffield, UK: Marie Curie Fellowship, 2003
     – 2003
  • Harvard Medical School: Fulbright Scholarship, 2014
     – 2014
  • Centre for Environmental Research, Spain: Erasmus Fellowship, 2012
     – 2012

Education and Training

  • Faculty of Medicine, University of Thessaloniki — MD — 11/2000 — Medicine
  • Faculty of Medicine, University of Crete, Greece — PhD — 07/2005 — Epidemiology
  • Centre for Research in Environmental Epidemiology, , Barcelona, Spain — Post-doctoral Training — 12/2006 — Birth Cohort Researh
  • Venizelio General Hospital, Heraklion, Greece — Residency in Family Medicine — 02/2008 — Family Medicine

Research Funding

  • Translational Research Program on PFAS and Metabolic Diseases: A Solution Oriented Framework
    NIH · R35ES035051 · Apr 10, 2026 – Mar 31, 2034 · Role: Principal Investigator
  • PFAS and liver cancer: linking epidemiological evidence with mechanistic studies
    NIH · R01CA300355 · Apr 1, 2026 – Mar 31, 2031 · Role: Co-Principal Investigator
  • Southern California Superfund Research and Training Program for PFAS Assessment, Remediation, and Prevention (ShARP)
    NIH · P42ES036506 · Apr 24, 2025 – Jan 31, 2030 · Role: Principal Investigator
  • PFAS and bone health over the life course in Hispanic/Latinos: emerging risk factors and underlying mechanisms
    NIH · R01ES036253 · Jan 3, 2025 – Dec 31, 2029 · Role: Principal Investigator
  • Pediatric Autoimmune Consortium for Exposome Research (PACER)
    NIH · R21AR084040 · Sep 22, 2023 – Aug 31, 2025 · Role: Co-Principal Investigator
  • Longitudinal integration of environmental exposures, omics, and childhood NAFLD (LEON) Study
    NIH · U01HG013288 · Sep 12, 2023 – May 31, 2028 · Role: Principal Investigator
  • Hepatotoxic effects of perfluoroalkyl substances: a new epidemiological approach for studying environmental fatty liver disease
    NIH · R01ES030691 · May 1, 2020 – Apr 30, 2024 · Role: Principal Investigator
  • Effects of DDE exposure on adipose tissue function, weight loss and metabolic improvement after bariatric surgery: A new paradigm for study of lipophilic chemicals
    NIH · R01ES030364 · Feb 1, 2020 – Nov 30, 2024 · Role: Principal Investigator
  • Environmental Chemical Exposures and Longitudinal Changes of Glucose Metabolism, Insulin Sensitivity and B Cell Function in Youth
    NIH · R01ES029944 · Aug 15, 2019 – May 31, 2025 · Role: Principal Investigator
  • Developmental origins of child liver injury: Effects of prenatal environmental exposures
    NIH/NIEHS · R21 ES0293281 · May 1, 2019 – Apr 30, 2021 · Role: PI
  • Developmental origins of child liver injury: Effects of prenatal environmental exposures
    NIH · R21ES029681 · May 1, 2019 – Apr 30, 2021 · Role: Principal Investigator
  • The adipose exposome effects on the plasma metabolome, body composition and metabolic outcomes after bariatric surgery
    NIH · R21ES028903 · Jul 15, 2018 – Jun 30, 2021 · Role: MPI
  • LIFECYCLE – Early Life Stressors and Lifecycle Health
    European Commission · Jan 1, 2017 – Dec 31, 2020 · Role: Task Leader
  • Lifecourse Approach to Developmental Repercussions of Environmental Agents on Metabolic and Respiratory health (LA DREAMERs)
    NIH · UG3OD023287 · Sep 21, 2016 – Aug 31, 2018 · Role: Co-Investigator
  • Environmental Exposures, Host Factors and Human Disease
    NIH · P30ES007048 · Apr 1, 1996 – Apr 30, 2031 · Role: Co-Investigator

Research Keywords

  • environmental epidemiology; birth cohort research; childhood obesity; endocrine disrupting chemicals

Publications

  • Associations between Exposure to Perfluoroalkyl Substances with Subsequent Body Composition and Glycemic Responses to Bariatric Surgery. medRxiv. 2026 Apr 01.. View in PubMed
  • Exposure to Per- and Polyfluoroalkyl Substances and Liver Cancer: A Systematic Review of Animal and Epidemiological Studies. Environ Sci Technol. 2026 Feb 03; 60(4):2816-2831.. View in PubMed
  • Associations of perfluoroalkyl and polyfluoroalkyl substances with markers of glycaemic control, insulin secretion and sensitivity, and diabetes risk: a systematic review and meta-analyses. EClinicalMedicine. 2026 Feb; 92:103747.. View in PubMed
  • Developmental perfluorooctane sulfonate (PFOS) exposure alters gene expression in nucleus accumbens and prefrontal cortex and impairs cognition in rats: A transcriptomic and mediation analysis. Ecotoxicol Environ Saf. 2026 Jan 01; 309:119648.. View in PubMed
  • Polyfluoroalkyl substances and altered glucose homeostasis in adolescents following bariatric surgery. Environ Endocrinol. 2026 Jan; 2(1):wkaf003.. View in PubMed
  • Associations between per- and polyfluoroalkyl substances and metabolic dysfunction-associated steatotic liver disease in adolescents and young adults: modifying roles of age, lifestyle factors, and PNPLA3 genotype. Environ Res. 2026 Jan 01; 288(Pt 2):123320.. View in PubMed
  • Synergistic toxicity in alcohol-associated liver disease and PFAS exposure. Toxicol Sci. 2025 11 01; 208(1):9-31.. View in PubMed
  • Mediating role of proteomics in the association between per- and polyfluoroalkyl substance exposure and blood pressure in youth. Environ Pollut. 2025 Dec 15; 387:127336.. View in PubMed
  • Dietary Macronutrient Intake and the Gut Microbiome in Adults Undergoing Bariatric Surgery for Obesity. medRxiv. 2025 Oct 30.. View in PubMed
  • Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents. Hypertension. 2025 Dec; 82(12):2183-2196.. View in PubMed